Compare CTRN & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRN | AGMB |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.1M | 576.2M |
| IPO Year | 2005 | 2024 |
| Metric | CTRN | AGMB |
|---|---|---|
| Price | $43.76 | $6.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $91.00 | $37.67 |
| AVG Volume (30 Days) | 217.7K | ★ 274.9K |
| Earning Date | 12-01-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.14 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $819,962,000.00 | N/A |
| Revenue This Year | $10.94 | N/A |
| Revenue Next Year | $8.69 | N/A |
| P/E Ratio | $54.66 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $36.05 | $5.73 |
| 52 Week High | $77.91 | $17.82 |
| Indicator | CTRN | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 26.49 |
| Support Level | $42.53 | N/A |
| Resistance Level | $52.14 | $9.55 |
| Average True Range (ATR) | 3.52 | 0.85 |
| MACD | -0.31 | -0.03 |
| Stochastic Oscillator | 8.50 | 10.36 |
Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.